Proposed Combo Products Rule Underestimates Cost of GMPs

Devices & Diagnostics Letter
A A
The FDA’s proposed rule on good manufacturing practices (GMPs) for combination products grossly underestimates the burden of applying certain cGMP requirements to device-drug combinations, a device company says.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00